SavedAdd your journal

Journals / Türkderm Türk deri hastalıkları ve frengi arşivi / 2020 / Cilt: 54 - Sayı: 1

Comparison of the plasma levels of cathepsin-L and granulysin between patients with psoriasis and healthy controls

Psoriazis hastaları ve kontrol gruplarında plazma katepsin-L ve granulizin düzeylerinin karşılaştırılması

Müzeyyen GONUL
Sevim BAYSAK
Şeyda ŞAHINGOZ
Alpaslan OZTURK
Havva Hilal AYVAZ
Pages
15–18
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However,according to the results of this study, CL and GNLY levels are not sufficient markers to indicate the level of cellular immunity and disease severityin psoriasis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Psoriasis is a chronic papulosquamous disease where histologically epidermal hyperproliferation and infiltrationinvolving natural killer cells and cytotoxic T-cells are observed.
📊
Key Findings & Data:In this study, we investigated the relationship between the severityand duration of psoriasis and the levels of CL and GNLY.Materials and Methods: Prospective and randomized study of 40 patients (23 males, 17 females) with psoriasis who admitted to hospitalbetween December 2014 and August 2015, and 40 age and sex-matched healthy controls (23 males, 17 females) were investigated.
💡
Conclusion & Impact:However,according to the results of this study, CL and GNLY levels are not sufficient markers to indicate the level of cellular immunity and disease severityin psoriasis.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Background and Design: Psoriasis is a chronic papulosquamous disease where histologically epidermal hyperproliferation and infiltrationinvolving natural killer cells and cytotoxic T-cells are observed. These cells have been shown to carry cytolytic molecules containing high amountof perforin, granzyme B and granulysin (GNLY). The roles of these molecules in the pathogenesis of psoriasis are still disputed, with serum GNLYand cathepsin-l (CL) levels thought to be associated with cellular immunity. In this study, we investigated the relationship between the severityand duration of psoriasis and the levels of CL and GNLY.Materials and Methods: Prospective and randomized study of 40 patients (23 males, 17 females) with psoriasis who admitted to hospitalbetween December 2014 and August 2015, and 40 age and sex-matched healthy controls (23 males, 17 females) were investigated. CL andGNLY serum levels were measured by ELISA method.Results: There was no significant differences in GNLY and CL levels between psoriasis patients and the control group (p=0.243 and p=0.606).There was also no statistically significant difference between psoriasis patients with low Psoriasis Area Severity Index (PASI) (≤10) and thosewith high PASI (>10) (p=0.86 and p=0.61) score.Conclusion: There are studies that have shown GNLY and CL in the psoriazis are important markers for disease pathogenesis. However,according to the results of this study, CL and GNLY levels are not sufficient markers to indicate the level of cellular immunity and disease severityin psoriasis. Future studies are needed on this subject with a wider range of patients.

Özet

Amaç: Psoriazis, histolojik olarak epidermal hiperproliferasyon ve doğal katil hücreler ile sitotoksik T-hücreleri içeren infiltrasyonun gözlendiği, kronik papüloskuamöz bir hastalıktır. Bu hücrelerin yüksek miktarda perforin, granzim B ve granulizin (GNLY) içeren sitolitik molekülleri taşıdığı gösterilmiştir. Bu moleküllerin psoriazis patogenezindeki rolleri hala tartışmalıdır, serum GNLY ve katepsin-L (CL) seviyelerinin selüler immünite ile ilişkili olabileceği düşünülmektedir. Bu çalışmada psoriaziste hastalık şiddeti ve süresiyle, CL ve GNLY seviyelerinin ilişkisini araştırdık. Gereç ve Yöntem: Prospektif ve randomize bu çalışmaya, Aralık 2014-Ağustos 2015 tarihleri arasında başvuran 40 psoriazis (23 erkek, 17 kadın) hastası ile yaş, cinsiyet uyumlu 40 gönüllü (23 erkek, 17 kadın) dahil edildi. CL ve GNLY serum seviyeleri ELISA yöntemiyle ölçüldü. Bulgular: CL ve GNLY seviyelerinde, psoriazis hastaları ve kontrol grubu arasında istatistiksel olarak anlamlı fark yoktu (p=0,243 ve p=0,606). Düşük Psoriazis Alan Şiddet İndeksi (PAŞİ) skoru (≤10) olan psoriazis hastaları ile yüksek PAŞİ skoru (>10) olan hastalar arasında da istatistiksel olarak anlamlı fark yoktu (p=0,86 ve p=0,61). Sonuç: Psoriyatik deride bakılan CL ve GNLY’nin, hastalık patogenezi açısından önemli belirteçler olduğuyla ilgili çalışmalar mevcuttur. Fakat bu çalışmanın sonucuna göre, CL ve GNLY seviyelerinin, psoriaziste hücresel immünite düzeyini ve hastalık şiddetini göstermede yeterli belirteçler olmadıkları düşünülmektedir. Bu konuda daha geniş hasta serileri ile ileri çalışmalar yapılmasına ihtiyaç vardır

🔖

Cite This Article

GONUL, M., BAYSAK, S., ŞAHINGOZ, Ş., OZTURK, A., AYVAZ, H. H. (2022). Comparison of the plasma levels of cathepsin-L and granulysin between patients with psoriasis and healthy controls. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 54 - Sayı: 1, 15–18. https://ajindex.com/articles/622478

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Griffiths CE, Baker JN: Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
  2. Azfar RS, Gelfand JM: Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416-22.
  3. Özden MG, Tekin NS: Psoriasis patogenezinde yenilikler. Türkiye Klinikleri J Dermatol 2007;17:112-9. Roberts R: Lysosomal cysteine proteases: Structure, function and inhibition of cathepsins. Drug News Perspect 2005;18:605-14.
  4. Ochoa MT, Stenger S, Sieling PA, et al: T-cell release of granulysin contributes to host defense in leprosy. Nat Med 2001;7:174-9.
  5. Shi GP, Bryant RAR, Riese R, et al: Role for cathepsin F in in variant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000;191:1177-86.
  6. Kos J, Jevnikar Z, Obermajer N: The role of cathepsin X in cell signaling. Cell Adh Migr 2009;3:164-6.
  7. Gamen S, Hanson DA, Kaspar A, Naval J, Krensky AM, Anel A: Granulysin induced apoptosis. I. Involvement of at least two distinct pathways. J Immunol 1998;161:1758-64.
  8. Ogawa K, Takamori Y, Suzuki K, et al: Granulysin in human serum as a marker of cell-mediated immunity. Eur J Immunol 2003;33:1925-33.
  9. Dubois Declercq S, Pouliot R: Promising new treatments for psoriasis. Scientific World Journal 2013;2013:980419. Ergun T: Psoriasisin Etyopatogenezi. Turkderm 2008;42:18-22.
  10. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009;361:496-509.
  11. Russell JH, Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-70.
  12. Hibino T, Fukuyama K, Epstein WL: In vitro and in vivo inhibition of rat liver cathepsin L by epidermal proteinase inhibitor. Biochem Biophys Res Commun 1980;93:440-7.
  13. Cunnane G, FitzGerald O, Hummel KM, Gay RE, Gay S, Bresnihan B: Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford) 1999;38:34-42.
  14. Bylaite M, Moussali H, Marciukaitiene I, Ruzicka T, Walz M: Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases. Exp Dermatol 2006;15:110-8.
  15. Kawada A, Hara K, Kominami E, Hiruma M, Noguchi H, Ishibashi A: Processing of cathepsins L, B and D in psoriatic epidermis. Arch Dermatol Res 1997;289:87-93.
  16. Ohtani O, Fukuyama K, Epstein WL: Biochemical properties of thiol proteinase inhibitor purified from psoriatic scales. J Invest Dermatol 1982;78:280-4.
  17. Cheng T, Tjabringa GS, van Vlijmen-Willems IM, et al: The cystatin M/Econtrolled pathway of sk